Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Paion AG
  6. Summary
    PA8   DE000A0B65S3

PAION AG

(PA8)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
1.826(c) 1.776(c) 1.836(c) 1.784(c) 1.816 Last
48 471 20 456 69 054 42 640 66 235 Volume
+3.05% -2.74% +3.38% -2.83% +1.79% Change
More quotes
Estimated financial data (e)
Sales 2021 9,78 M 11,3 M 11,3 M
Net income 2021 -12,5 M -14,5 M -14,5 M
Net Debt 2021 6,95 M 8,06 M 8,06 M
P/E ratio 2021 -9,91x
Yield 2021 -
Sales 2022 33,2 M 38,4 M 38,4 M
Net income 2022 -18,3 M -21,2 M -21,2 M
Net Debt 2022 29,7 M 34,4 M 34,4 M
P/E ratio 2022 -6,32x
Yield 2022 -
Capitalization 127 M 148 M 148 M
EV / Sales 2021 13,7x
EV / Sales 2022 4,73x
Nbr of Employees 43
Free-Float 90,9%
More Financials
Company
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed... 
More about the company
Ratings of Paion AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about PAION AG
09/16PAION : Announces initiation of pivotal study of remimazolam (byfavo(r)) in pediatric proc..
EQ
09/16PRESS RELEASE : Paion ag announces initiation of pivotal study of remimazolam (byfavo(r)) ..
DJ
09/02PRESS RELEASE : Paion signs exclusive uk supply and distribution agreement with clinigen
DJ
09/02PAION : Signs exclusive uk supply and distribution agreement with clinigen
EQ
09/02Paion AG Signs Exclusive UK Supply and Distribution Agreement with Clinigen Group plc
CI
09/02Clinigen Group plc Signs an Exclusive Partnership Agreement with Paion for the Supply a..
CI
09/01PAION : Launches xerava(r) (eravacycline) for the treatment of complicated intra-abdominal..
EQ
09/01PRESS RELEASE : Paion launches xerava(r) (eravacycline) for the treatment of complicated i..
DJ
09/01PAION AG Launches XERAVA(R) (Eravacycline) for the Treatment of Complicated Intra-Abdom..
CI
08/31PRESS RELEASE : Paion ag: hana pharm receives market approval for byfavo (remimazolam) in ..
DJ
08/31PAION AG : Hana pharm receives market approval for byfavo (remimazolam) in procedural seda..
EQ
08/23PAION : Reports financial resultsáfor the first half-year 2021
EQ
08/23PRESS RELEASE : Paion ag reports financial results -3-
DJ
08/23PRESS RELEASE : Paion ag reports financial results -2-
DJ
08/23PRESS RELEASE : Paion ag reports financial results for the first half-year 2021
DJ
More news
News in other languages on PAION AG
09/16Paion ag gibt start einer zulassungsrelevanten studie für remimazolam (byfavo(r)) in de..
09/16Paion ag gibt start einer zulassungsrelevanten studie für remimazolam (byfavo(r)) in de..
09/02PAION : Unterzeichnet exklusiven liefer- und distributionsvertrag mit clinigen für das ver..
09/02Paion unterzeichnet exklusiven liefer- und distributionsvertrag mit clinigen für das ve..
09/01Paion startet vermarktung von xerava(r) (eravacyclin) für die behandlung komplizierter ..
More news
Analyst Recommendations on PAION AG
More recommendations
Chart PAION AG
Duration : Period :
Paion AG Technical Analysis Chart | PA8 | DE000A0B65S3 | MarketScreener
Technical analysis trends PAION AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,78 €
Average target price 4,01 €
Spread / Average Target 125%
EPS Revisions
Managers and Directors
James Neil Phillips Chief Executive Officer
Abdelghani Omari Chief Financial Officer
J÷rg Spiekerk÷tter Chairman-Supervisory Board
Karin Louise Dorrepaal Vice Chairman-Supervisory Board
Irina Antonijevic Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
PAION AG-24.32%148
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455